Nova Eye Medical Limited announced that its AlphaRET division has completed the initial recruitment of investigator sites for the Company's planned 2RT® Confirmatory Pivotal Study. In a significant milestone in the Company's plans to conduct the multi-center confirmatory study, which is intended to validate the results of the 2018 "LEAD" Study, twenty-eight (28) of the world's leading retinal researchers and clinical experts across Europe, Canada and Australia have confirmed their participation in the study, including Robert Finger, PhD, MD. Professor and Consultant Ophthalmologist from the Department of Ophthalmology at the University of Bonn, Germany, Prof. Dr. Finger is a leading authority in age-related macular degeneration (AMD) research. The Confirmatory Pivotal Study will be led by Robyn Guymer, AM FAHMS, Deputy Director of the Centre for Eye Research Australia (CERA), the Head of Macular Research at CERA and Professor of Ophthalmology at Melbourne University. Prof. Guymer was the Principal Investigator for the LEAD Study. 2RT® is a proprietary, world first nanosecond laser therapy to treat age-related macular
degeneration in its intermediate stage. It works by stimulating the rejuvenation of cells in the retina to initiate a healing response that targets the underlying causes of AMD. Importantly, 2RT® has the potential to transform the global treatment of AMD by treating patients earlier in the disease state. This represents a revolutionary change from the status quo, in which patients undergo treatment late in the disease process, by which time significant vision loss has already occurred. AlphaRET is progressing discussions with potential equity partners to fund the completion of the 2RT® Confirmatory Pivotal Study.